Structural plasticity of KIR2DL2 and KIR2DL3 enables altered docking geometries atop HLA-C by Moradi, Shoeib et al.
Article
Structural plasticity of KIR2DL2 and KIR2DL3 
enables altered docking geometries atop HLA-C
Moradi, Shoeib, Stankovic, Sanda, O'connor, Geraldine, Pymm, Phillip, 
MacLachlan, Bruce J., Faoro, Camilla, Retiere, Christelle, Sullivan, Lucy C., 
Saunders, Philippa M. and Et, Al
Available at http://clok.uclan.ac.uk/37529/
Moradi, Shoeib, Stankovic, Sanda, O'connor, Geraldine ORCID: 0000-0002-7440-162X, 
Pymm, Phillip, MacLachlan, Bruce J., Faoro, Camilla, Retiere, Christelle, Sullivan, Lucy 
C., Saunders, Philippa M. et al (2021) Structural plasticity of KIR2DL2 and KIR2DL3 
enables altered docking geometries atop HLA-C. Nature Communications, 12 (2173).  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1038/s41467-021-22359-x
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/resear  c  h/   
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained by the 
individual authors and/or other copyright owners. Terms and conditions for use of this material 
are defined in the po  l icies   page.
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
ARTICLE
Structural plasticity of KIR2DL2 and KIR2DL3
enables altered docking geometries atop HLA-C
Shoeib Moradi1,2,8, Sanda Stankovic3,8, Geraldine M. O’Connor4,8, Phillip Pymm1,2, Bruce J. MacLachlan 1,
Camilla Faoro 1, Christelle Retière5,6, Lucy C. Sullivan3, Philippa M. Saunders 3, Jacqueline Widjaja 3,
Shea Cox-Livingstone3, Jamie Rossjohn 1,2,7,9✉, Andrew G. Brooks 3,9✉ & Julian P. Vivian 1,2,9✉
The closely related inhibitory killer-cell immunoglobulin-like receptors (KIR), KIR2DL2 and
KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human
leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are
highly polymorphic, with this variation being associated with differences in the onset and
progression of some human diseases. However, the molecular bases underlying these
associations remain unresolved. Here, we determined the crystal structures of KIR2DL2 and
KIR2DL3 in complex with HLA-C*07:02 presenting a self-epitope. KIR2DL2 differed from
KIR2DL3 in docking modality over HLA-C*07:02 that correlates with variabilty of recognition
of HLA-C1 allotypes. Mutagenesis assays indicated differences in the mechanism of HLA-C1
allotype recognition by KIR2DL2 and KIR2DL3. Similarly, HLA-C1 allotypes differed markedly
in their capacity to inhibit activation of primary NK cells. These functional differences derive,
in part, from KIR2DS2 suggesting KIR2DL2 and KIR2DL3 binding geometries combine with
other factors to distinguish HLA-C1 functional recognition.
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Natural killer (NK) cells discriminate between healthy andinfected or transformed cells using an array of germline-encoded inhibitory and activating receptors1,2. Central
to this process is the interaction between the killer cell
immunoglobulin-like receptors (KIR) and their cognate ligands,
human leukocyte antigen class I molecules (HLA-I)3–5. In
humans, three highly polymorphic loci encode classical HLA-I
genes, HLA-A, -B and -C, the latter being particularly important
for regulating NK cell function6. HLA-C alleles are divided into
two groups, C1 and C2 based on dimorphisms at positions 77 and
80 located on the α1-helix of the antigen-binding cleft with the
dimorphism at position 80 in particular being a critical specificity
determinant for some KIR. HLA-C1 allotypes, which are char-
acterised by an asparagine at position 80 are the preferred ligands
for the inhibitory receptors KIR2DL2 and KIR2DL3 whereas
HLA-C2 allotypes encode a lysine at this position and are
recognised by KIR2DL17,8. A primary specificity difference
between KIR2DL1, KIR2DL2 and KIR2DL3 has been attributed
to the presence of a methionine at position 44 in KIR2DL1
compared with a lysine in KIR2DL2 and KIR2DL38.
Analyses of the specificity of KIR2DL1, -2DL2 and -2DL3 has
been assessed using KIR-Fc-fusion proteins9–12 and suggested
that KIR2DL2 and KIR2DL3 are more broadly HLA-C1/C2
cross-reactive than KIR2DL110,11. Such studies have also sug-
gested that KIR2DL2 has a greater avidity than KIR2DL3 for
HLA-C1 group allotypes, a greater breadth of binding across the
HLA-C2 group along with the capacity to interact with a broader
array of peptides9,12,13. While the KIR2DL2/3 receptors share
~94% sequence identity and segregate as alleles of a single locus,
they are inherited on different KIR haplotypes14–18, which has
implications for NK cell function. For instance, the expression of
KIR2DL1 is epistatically suppressed by the expression of
KIR2DL2, a phenomenon not observed with KIR2DL319. Simi-
larly, KIR2DS2 is in linkage disequilibrium with KIR2DL2 and not
KIR2DL320. Moreover, these differences are associated with dif-
ferent clinical outcomes. For example, in the presence of HLA-C1
alleles, KIR2DL3 but not KIR2DL2 has been associated with
clearance of hepatitis-C infection21,22 as well as the progression of
ulcerative colitis23. However, the mechanistic basis of these
selective associations is not well defined.
The structures of KIR2DL1 in complex with peptide (p)-HLA-
C*04:01 and KIR2DL2 bound to pHLA-C*03:04 show a con-
served binding mode, with the C-terminus of the peptide sitting
at the junction of the two domains of the KIR (D1 and D2) and
the D1 and D2 domains of the KIR2DL receptors docking on the
α1- and α2-helices of the HLA-C, respectively. While the KIR2DL
contacts with the α2-helix are conserved, interactions with both
the peptide and the α1-helix vary, consistent with the ability of
KIR2DL1 and 2DL2 to discriminate between HLA-C1 and HLA-
C2 allotypes and different peptides bound to individual HLA-I
allotypes9,12,24–28.
Presently, a molecular basis for any functional differences
between KIR2DL2 and KIR2DL3 is unknown. Here, we deter-
mined the crystal structures of KIR2DL2 and KIR2DL3 in com-
plex with pHLA-C*07:02, which showed that KIR2DL2 and
KIR2DL3 engage HLA-C1 with different docking angles. More-
over, via mutagenesis and binding studies, we show that
KIR2DL2 and KIR2DL3 utilise similar frameworks of contact
residues to recognise HLA-C, yet do so in a manner that is
dependent on the allotype of HLA-C1 molecule itself. These
structural distinctions provide insights into how KIR2DL2 and
KIR2DL3 can discriminate between similar HLA-C allotypes.
Nevertheless, in vitro analyses of primary NK cells bearing either
KIR2DL2 or KIR2DL3 suggest that the functional impact is subtle
and that understanding differences between KIR2DL2 and
KIR2DL3 in clinical settings may be confounded by co-expression
of activating receptors with specificity for C1 allotypes.
Results
KIR2DL2 shows distinct binding to HLA-C*03:04 and HLA-
C*07:02. We determined the crystal structure of KIR2DL2 in
complex with HLA-C*07:02 presenting a self-peptide derived
from histone H3 (RL9, residues 40–48, RYRPGTVAL)29. To date,
crystal structures of KIR2DL1, KIR2DL2, KIR2DS2 with single
HLA allotypes as well as KIR3DL1 in complex HLA-B*57:01 and
-B*57:03 have been determined24,25,30,31. The structure of
KIR2DL2 in complex with HLA-C*03:04-GAVDPLLAL (GL9)
was previously determined24, and together with our structure of
KIR2DL2 in complex with HLA-C*07:02-RL9 provided an
opportunity to compare how allelically related KIR2D recognise
distinct HLA-I allotypes (Figs. 1a, b and 2a, b).
The KIR2DL2-HLA-C*07:02-RL9 ternary complex was deter-
mined to 3.1 Å resolution and displayed unambiguous density at
the KIR2DL2/HLA-C interface allowing for ready interpretation
(Supplementary Table 1, Supplementary Fig. 1). The crystal
lattice contained two ternary complexes in the asymmetric unit
that were highly similar (root mean square deviation (r.m.s.d.)
<0.4 Å over all Cα positions), and accordingly, one copy of the
complex was used for analysis. Overall, the binding of KIR2DL2




























































Fig. 1 Structural comparison of KIR2DL2 in complex with HLA-C*07:02-
RL9 and HLA-C*03:04-GL9. a Overall structure of KIR2DL2 in complex
with HLA-C*07:02-RL9. The complex is represented in cartoon format with
KIR2DL2 coloured pink, HLA-C*07:02 coloured grey, β2m coloured orange
and the peptide coloured magenta. b Comparison of KIR2DL2 in complex
with HLA-C*03:04-GL9 (KIR coloured green) and HLA-C*07:02-RL9 (KIR
coloured pink). The relative difference in hinge and twist angles of the KIR is
shown. Footprints of KIR2DL2 on HLA-C*07:02-RL9 (c) and HLA-C*03:04-
GL9 (d) coloured by domain binding. D1 contacts coloured green, D1-D2
interdomain loop contacts coloured red and D2 contacts coloured orange.
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KIR2D-pHLA ternary complexes, with the elbow-angle of the
receptor formed by the junction of the KIR2D C-type
immunoglobulin domains (D1 and D2) characteristically strad-
dling the centre of the HLA peptide-binding groove and
positioned over the C-terminus of the peptide (Fig. 1a). This
arrangement placed the KIR D1 domain over the HLA α1-helix
that was bound via three KIR2DL2 loops, A-B, C-C′ and E-F,
with canonical contacts to the HLA-lineage defining Asn80 by the
C-C′ residue Lys44 (Fig. 1a, c, Supplementary Fig. 2a, Supple-
mentary Table 2). The HLA-I α2-helix was recognised via two
loops of the D2 domain; the B-C loop spanning Ser132 to Asp135
and the F-F′ loop that spans Phe181 to Glu187 as well as the D1-
D2 interdomain loop (Fig. 1a, c, Supplementary Fig. 2b,
Supplementary Table 2).
Comparing the structure of KIR2DL2-HLA-C*07:02-RL9 with
the previously determined structure of KIR2DL2-HLA-C*03:04-
GL9 (PDB accession code 1EFX24) revealed very similar docking
modes. The buried surface area (B.S.A.) of the two ternary
complexes were similar (KIR2DL2-HLA-C*03:04 ~1600 Å2,
KIR2DL2-HLA-C*07:02 ~1700 Å2). All residues on KIR2DL2
that contacted HLA were also conserved between the KIR2DL2
complexes. Indeed, of the 21 polymorphisms that distinguish
HLA-C*03:04 from HLA-C*07:02, nine map to the peptide-
binding groove and while impacting peptide repertoire, none
directly contacted KIR2DL2. Moreover, there were conserved
contacts to the P7 and P8 positions of the GL9 and RL9 peptides,
mediated by Gln71KIR2DL2 and Leu104KIR2DL2 (Supplementary
Fig. 3). Notwithstanding the sequence differences, HLA-C*03:04
and C*07:02 superposed very closely with a r.m.s.d. of 0.9 Å (over
Cα residues 1–180). Yet, there was a difference observed at the
binding site for the D2 domain of KIR2DL2 on the α2-helix linker
(residues 149–153) that deviated by 1.8 Å (Supplementary
Fig. 2c).
While there was a highly similar hinge angle for the KIR2DL2
receptor (76.1° for 2DL2-HLA-C*07:02 and 77.7° for 2DL2-HLA-
C*03:04) (Fig. 1b), the docking of KIR2DL2 differed about the twist of
the receptor by 5.2° for D1 domains and 9.8° for D2 domains (Fig. 1b,
Supplementary Fig. 4), where twist is defined as the rotation of the
KIR2DL domains about their short axis, perpendicular to the short axis
that defines the hinge angle (shown in Fig. 1b). As a result, this led to
some subtle differences in the contact points between these two HLA-
C allomorphs (Fig. 1a–c, Supplementary Fig. 2a, b, Supplementary
Table 2). Namely, KIR2DL2 made more unique contacts to HLA-
C*07:02. Specifically, Pro20C*07:02 interacted with Phe45KIR2DL2,
Val76C*07:02 interacted with and Lys44KIR2DL2 and Glu187KIR2DL2
and Lys146C*07:02 and Ala149 C*07:02 contacted Glu187KIR2DL2 and
Tyr134KIR2DL2, respectively (Fig. 1c, d, Supplementary Fig. 2a). By
contrast, the only contacts observed in the KIR2DL2-HLA-C*03:04
ternary complex and not in the C*07:02-RL9 were, Arg75C*03:04
contacted Asp72KIR2DL2, and Tyr105 KIR2DL2 contacted P7-Val of the
RL9 peptide (Fig. 1c, d, Supplementary Figs. 2b and 3). Taken together,
KIR2DL2 used the same framework of D1 and D2 residues to
recognise subtly different regions on these distinct HLA-C allotypes,
with the twist angle providing the basis of the differences between these
two ternary KIR2DL2-pHLA-C complexes.
KIR2DL2 and KIR2DL3 show distinct docking modes to
pHLA-C*07:02. Next, we next determined the crystal structure of
KIR2DL3*001 in complex with HLA-C*07:02 bound to the RL9
peptide. This allowed for structural comparison of two KIR2DL
allomorphs bound to the same HLA-peptide complex. The
KIR2DL3 ternary complex was determined to 2.5 Å resolution
(Fig. 2a, Supplementary Table 1).
Overall, the binding of KIR2DL3 to HLA-C*07:02-RL9 largely
recapitulated that observed for KIR2DL2-HLA-C*07:02-RL9
(and other KIR2D-HLA complexes)24,25,30. Namely, the D1
domain interacted with the HLA α1-helix via the A-B, C-C′ and
E-F loops, whilst two recognition loops of the D2 domain (B-C
and F-F′) and the D1-D2 interdomain loop made contacts with
the HLA α2-helix (Fig. 2a, Supplementary Table 2). KIR2DL2 and
KIR2DL3 adopted highly similar hinge angles of 77.7° and 77.1°,
respectively (Fig. 2b). Individually, the D1 and D2 domains
aligned with r.m.s.d. values of 0.45 Å (residues 1–102) and 0.61 Å
(residues 108–200), respectively. Yet, despite this structural
homology, differences were observed in the relative juxtaposi-
tioning of the D1 and D2 domains of KIR2DL2/3. Specifically, the
structural differences between KIR2DL2 and KIR2DL3 centred
on the twist of the D1 and D2 domains that differed by 13.3° for
the D1 and 10.4° for the D2 domains (Fig. 2b, c).
The extracellular domains of KIR2DL2*001 and KIR2DL3*001
differ at positions 16, 35, 148 and 200 (Fig. 2e). Of these, positions
35 (Glu35Gln) and 200 (Ile200Thr) are located distal to the hinge
on the membrane-proximal side of the D1 and D2 domains,
respectively (Fig. 2e). In contrast, both Arg16Pro (D1 A-A′ loop)



































































Fig. 2 Structural comparisons of KIR2DL2 and 2DL3 in complex with
HLA-C*07:02-RL9. a Overall structure of KIR2DL3 in complex with HLA-
C*07:02-RL9. The complex is represented in cartoon format with KIR2DL2
coloured blue, HLA-C*07:02 coloured grey, β2m coloured orange and the
peptide coloured cyan. b Comparison of KIR2DL2 (pink) and 2DL3 (blue) in
complex with HLA-C*07:02-RL9. The relative difference in hinge and twist
angles of the KIR is shown. c Footprint of KIR2DL3 on HLA-C*07:02-RL9
coloured by domain binding. D1 contacts coloured green, D1-D2
interdomain loop contacts coloured red and D2 contacts coloured orange.
d Comparison of KIR2DL2 (pink) and KIR2DL3 (blue) D1 contacts to the α1-
helix of HLA-C*07:02-RL9 (KIR2DL2 contacts coloured grey, KIR2DL3
contacts coloured cyan). The ~3 Å shifts of the D1 C-C′ and E-F loops are
highlighted. e Mapping of sequence differences to the structures of
KIR2DL2/3. Differences highlighted as blue spheres.
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D1-D2 hinge with these loops spanning the D1-D2 domain
junction. Here, Arg16KIR2DL2 reached across the D1-D2 interface
adjacent the D2 C-C′ loop binding His146KIR2DL2, while
Pro16KIR2DL3 made no direct interdomain interaction (Supple-
mentary Fig. 5a). Notably, KIR2DL1*001 (PDB code 1IM925)
contains a Pro at residue 16, and possesses an Arg at position 148.
Given that KIR2DL1 displays a highly similar twist angle to
KIR2DL3, with relative differences of 3.6° on the D1 and 0.8° for
the D2 domain (Supplementary Fig. 4c, d), this suggests that the
polymorphisms at positions 16 and 148 are likely drivers of the
relative positioning of the D1-D2 domains.
This differing D1-D2 domain configuration resulted in the
centre of mass of the D1 domain of KIR2DL3 sitting ~3 Å more
towards the C-terminus of the peptide-binding groove of HLA-
C*07:02 relative to that observed for KIR2DL2. It also resulted in
the same framework of KIR2DL3 residues binding subtly
different regions of HLA-C*07:02-RL9. Namely, for the D1
domain, KIR2DL2 made more extensive contacts to the HLA α1-
helix (20% more B.S.A. Fig. 2c). These additional contacts
comprised residues Lys44KIR2DL2 and Phe45KIR2DL2 (C-C′ loop)
that interacted with Val76C*07:02 and Pro20C*07:02, respectively
(Fig. 2d). Furthermore, the D1 E-F loop shifted ~3.4 Å between
the complexes (Fig. 2b, d), which enabled additional contacts
involving Lys44KIR2DL2, Met70KIR2DL2, Gln71KIR2DL2 and
Asp72KIR2DL2 contacting Gln72C*07:02 and Val76C*07:02 (Fig. 2d,
Supplementary Table 2). For KIR2DL3, there was an additional
contact between Asp72KIR2DL3 (E-F loop) and Arg75C*07:02
(Fig. 2d). Similarly, the D1-D2 interdomain loop and the D2
domains of KIR2DL2 and KIR2DL3 also exhibited differences in
their interactions with the α2-helix (Figs. 1c and 2c, Supplemen-
tary Fig. 5b). For the D1-D2 interdomain loop, a difference was
observed at Glu106KIR2DL2 interacting with Arg151C*07:02
(Figs. 1c and 2c, Supplementary Fig. 5b). Within the D2 domain,
Ser184KIR2DL2, Glu187KIR2DL2 and Tyr134KIR2DL2 made unique
contacts to Lys146C*07:02 and Ala149C*07:02 (Fig. 2c, Supplemen-
tary Fig. 5b). For KIR2DL3, unique contacts were formed between
Phe181KIR2DL3 and Asp183KIR2DL3 and Arg145C*07:02 and
Ile142C*07:02, respectively (Figs. 1c and 2c, Supplementary Fig. 5b,
Supplementary Table 2). Regarding peptide contacts, KIR2DL2
and KIR2DL3 formed conserved peptide contacts to the P7 and
P8 positions of the RL9 peptide via resides Leu104KIR2DL2/2DL3
and Gln71KIR2DL2/2DL3 respectively, yet KIR2DL2 made an
additional contact to P7-Leu via Leu104KIR2DL2 (Supplementary
Table 2, Supplementary Fig. 2). Accordingly, KIR2DL2 and
KIR2DL3 use a highly conserved constellation of residues to
interact with HLA-C molecules, yet the differing juxtapositioning
of the D1-D2 domains provides a framework from which might
impact recognition of different HLA-C1 allotypes.
HLA-C*03:04 and HLA-C*07:02 are not equivalent for
KIR2DL recognition. To evaluate the extent to which structural
variations across KIRDL2/3-HLA-C interactions correlated with
binding affinity, we probed the interaction of KIR2DL2 and
KIR2LD3 to HLA-C*03:04-GL9 and HLA-C*07:02-RL9. HLA-C
tetramers were used to stain 293T cells expressing matched levels
of either FLAG-tagged KIR2DL2/3 or cells bearing one of 14 ala-
nine point mutations at positions implicated in ligand recognition
and the proportion of tetramer-positive cells normalised against
the proportion of cells that stained with FLAG-specific mAb
(Fig. 3a–c). A comparison of the binding of the HLA-C*03:04-GL9
tetramer to KIR2DL2 and KIR2DL3 mutants revealed highly
similar patterns of contact residue dependence (Fig. 3b). Specifi-
cally, mutation of residues Phe45, Leu104, Tyr105, Asp135, Phe181
and Asp183 all significantly impacted binding of the HLA-C*03:04
tetramer to both KIR2DL2 and KIR2DL3 (Fig. 3b). Two
substitutions resulted in a statistically significant difference in
binding between KIR2DL2 and KIR2DL3 to HLA-C*03:04, namely
Lys44Ala (P= 0.0451) and Ser133Ala (P= 0.0096).
Similarly, staining of cells expressing wild-type or mutant
KIR2DL2 and KIR2DL3 with HLA-C*07:02-RL9 tetramer also
showed highly similar patterns of contact residue dependence
between KIR2DL2 and KIR2DL3. Nevertheless, the pattern of
dependence differed significantly from that observed for HLA-
C*03:04-GL9 with the staining of HLA-C*07:02 being less
perturbed by mutation (Fig. 3c). Specifically, alanine substitutions
at Phe45, Leu104, Ser133 and Asp183, all of which abrogated
HLA-C*03:04 recognition, were tolerated by HLA-C*07:02
(Fig. 3b, c). Indeed, the Tyr105Ala and Phe181Ala mutations
were the only substitutions that abrogated binding to the HLA-
C*07:02 tetramer (Fig. 3c). In addition, in contrast to HLA-
C*03:04 tetramer binding, for the HLA-C*07:02-RL9 tetramer,
only the Asp135Ala mutation showed a statistically significant
difference in binding to KIR2DL2 and KIR2DL3, the latter being
less tolerant of this substitution. Collectively, the data revealed
clear differences in the recognition mode of KIR2DL2 and
KIR2DL3 for HLA-C*03:04-GL9 and HLA-C*07:02-RL9. More-
over, the mutational analyses highlighted a degree of plasticity in
KIR2D recognition of C1 allotypes, where polymorphisms in the
KIR can alter the basis of ligand binding that may ultimately
impact the range of C1/peptide combinations that can be
recognised.
Distinct general characteristics of HLA-C recognition by
KIR2DL2 and KIR2DL3. As the above observations were based
on the KIR2DL recognition of HLA-C1 allotypes bound to a single
peptide, we next examined the extent to which differences between
KIR2DL2 and KIR2DL3 could be modulated by peptide repertoire.
We measured KIR2DL2 and KIR2DL3 binding via SPR to a panel
of twelve HLA-C*07:02-RL9 peptide substitutions which spanned a
variety of amino acids in the key KIR2DL contact regions P7 and
P8 (Table 1 and Supplementary Fig. 6). With the exception of P8F
and P8V, each substitution resulted in reduced affinity binding to
both KIR2DL2 and KIR2DL3 (Table 1). For example, inclusion of
the acidic resiude Glu at P7 or P8 was detrimental to binding of
both KIR2DLs in line with previous findings32. However, both
KIR2DL2 and KIR2DL3 shared similar binding preferences across
the peptides in this panel (Table 1). Thus, at least in the context of
the HLA-C*07:02-RL9 peptide, there were no marked differences
between KIR2DL2 and 2DL3 with respect to their sensitivity to P7
and P8 substitutions.
To evaluate KIR2DL binding in a broader context, soluble
tetrameric forms of KIR2DL2 and KIR2DL3 molecules were
generated and assessed for their ability to bind a panel of 97 bead-
bound HLA allotypes including 18 HLA-C1/C2 molecules, each
presenting a broad repertoire of peptides. As expected, both
KIR2DL2 and KIR2DL3 preferentially bound HLA-C1 molecules
over HLA-C2 molecules and exhibited minimal reactivity with
HLA-A and -B allotypes in the panel (Fig. 4a–c). Nevertheless,
there was considerable variation in the hierarchy of avidity for
different C1 allotypes. For example, KIR2DL2 bound HLA-
C*14:02 with only 14.7% of the avidity observed for the top
binding C1 allomorph, HLA-B*73:01. Indeed, C2 group allo-
morphs, such as HLA-C*15:02 and C*17:01, bound KIR2DL2 at
~55% of the top avidity, higher than a number of C1 group
allomorphs (e.g. HLA-C*12:03 and HLA-C*14:02) consistent
with previous observations suggesting KIR2DL2 had the potential
to cross react with C2 allotypes (Fig. 4a, b).
KIR2DL3 also preferentially bound HLA-C1 molecules over
HLA-C2 allotypes with broad recognition across HLA-C1
allomorphs. Namely, of the 11 HLA-C1 allotypes examined,
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KIR2DL3 bound 9 with greater than 75% of the maximum
avidity, with only HLA-C*14:02 interacting at modest levels (43%
of the maximum avidity). Moreover, in the case of KIR2DL3,
there was a clearer distinction between specificity for C1 and C2
allotypes with only the HLA-C*14:02 allotype interacting more
weakly than the highest binding C2 allotypes (Figs. 4a, c).
Comparing the binding preferences between KIR2DL2 and
KIR2DL3 at the level of individual HLA-C allomorphs showed
considerable variation. For example, the majority of the HLA-C1
allomorphs tended to be recognised with higher avidity by
KIR2DL3, with an average relative avidity across the group of
82.2% compared with 68.3% for KIR2DL2. Moreover, individual
HLA-C allomorphs also showed differences in binding preference
between the two KIR2DL receptors. For example, HLA-C*08:01
and HLA-C*12:03, bound considerably better to KIR2DL3 than
to KIR2DL2, whilst HLA-C*07:02 was bound with higher avidity
by KIR2DL2 (Fig. 4a–c). Accordingly, the data show that there
were distinct differences in the capacity of these allelically distinct
KIR2D to recognise individual C1 allotypes. Thus polymorphism
across both the KIR and HLA loci resulted in differences in the
strength of these receptor/ligand interactions.
Allotypic differences in HLA-C recognition by NK cells
expressing KIR2DL2 and KIR2DL3. To understand how differ-
ences in KIR2D/HLA-C interactions potentially translated to func-
tional outcomes, we initially compared NK cell recognition of three cell
lines isolated from Burkitt lymphoma patients; Raji (HLA-C*03:04/
C*04:01-C1/C2), Ramos (HLA-C*16:01-C1) and Namalwa (HLA-
C*07:01/07:02-C1/C1). Flow cytometric analyses showed that Raji and
Ramos expressed the similar levels of HLA-C with Namalwa having
slightly lower levels of expression as assessed by staining with the DT9
mAb (Fig. 5a). Primary NK cells were co-cultured with the lymphoma
lines or the HLA-I-deficient cell line 721.221 (221) and then stained
with an antibody panel that could distinguish between three popula-
tions of KIR2D-expressing cells; KIR2DL1/S1, KIR2DL1−KIR2DL2/
S2+KIR2DL3−(KIR2DL2/S2+) or KIR2DL1−KIR2DL2−KIR2DL3+



































































































































22 % 19 % 23 %
69 %









































































Fig. 3 Mapping the interaction between KIR2DL2/2DL3 to HLA-C*03:04-GL9 and C*07:02-RL9. 293T cells were transfected with plasmids encoding
either wild-type or mutant FLAG-tagged KIR2DL2 and KIR2DL3 and then stained with a FLAG-specific mAb or HLA-C*03:04-GL9 and HLA-C*07:02-RL9
tetramers. Representative dot plots showing staining to cells expressing wild-type KIR2DL2 and KIR2LD3 (a). Relative binding of wild-type (WT) KIR2DL2
and KIR2DL3 transfected 293T cells and their respective alanine mutants to phycoerythrin-conjugated tetramers of HLA-C*03:04-GL9 (b) and HLA-
C*07:02-RL9 (c). Transfected cells were stained for FLAG as a marker of KIR2DL expression and separately stained with HLA tetramers. Percentage
tetramer+ was normalised to percentage FLAG+ to account for differing KIR2DL transfection efficiency between mutants. The data represent a minimum
of n= 3 independent experiments; bar line=mean, error bars= standard error of the mean (SEM); individual data points= circles (2DL2) or squares
(2DL3). For each independent replicate, relative tetramer staining was normalised to staining of WT KIR2DL. Statistically significant differences in ligand
recognition between corresponding mutants of KIR2DL2 and KIR2DL3 as measured by Two-way ANOVA Šidák’s multiple comparison test are highlighted.
2DL2 (n= 5) vs. 2DL3 (n= 3) binding to C*03:04-GL9 K44A: *P= 0.0127; 2DL2 (n= 5) vs. 2DL3 (n= 3) binding to C*03:04-GL9 S133A: ***P= 0.0005;
2DL2 (n= 5) vs. 2DL3 (n= 3) binding to C*07-02-GL9 D135A: ***P= 0.0007.
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NK cells with Raji cells resulted in relatively similar levels of activation
of cells expressing KIR2DL1/S1, KIR2LD2/S2 or KIR2DL3 consistent
with their expression of both C1 and C2 allotypes (Fig. 5c, d). In
contrast, both the Ramos and Namalwa cell lines, which lack C2
allotypes, stimulated robust levels of degranulation of cells that
expressed KIR2DL1/S1. Despite modest differences in the level of
HLA-C expression, the extent of inhibition of KIR2DL2/S2 expressing
cells as reflected in the proportion of cells that expressed CD107a
compared to stimulation with 721.221 cells was similar between Ramos
and Namalwa. Similarly, the responses of cells that expressed KIR2DL3
were also comparable following coculture with Ramos and Namalwa.
Interestingly, the degranulation response of the KIR2DL2/S2+ popu-
lation to both Ramos and Namalwa was larger than that observed for
cells expressing KIR2DL3.
To extend the range of HLA-C allotypes assessed, NK cells from
donors who were heterozygous for KIR2DL2/3 were assayed for
their capacity to recognise .221 cells transfected with seven distinct
HLA-C allotypes. While .221 cells induced a robust response from
all three NK cell populations, expression of the C2 ligand HLA-
C*06:02, impaired activation of NK cells expressing KIR2DL1 but
had a less marked impact on the degranulation responses of cells
expressing either KIR2DL2/S2 or -2DL3 (Fig. 5e, f). In contrast, as
expected, expression of HLA-C1 allotypes inhibited the responses of
cells expressing KIR2DL2/S2 and KIR2DL3 but had limited impact
on the activation of cells expressing KIR2DL1/S1. As observed in
the bead-based binding assays, there were substantial differences in
the capacity of individual HLA-C1 allotypes to inhibit activation of
KIR2DL2/2DL3+ cells. For example, the expression of HLA-
C*03:02, HLA-C*07:02 or HLA-C*16:01 strongly inhibited degra-
nulation of cells expressing KIR2DL3, whereas cells expressing
allomorphs, such as HLA-C*03:04 had a more limited capacity to
inhibit NK cell activation. While the residues that contact




































































































































































Fig. 4 Single-antigen bead binding of KIR2DL2 and KIR2DL3. Binding of KIR2DL2 and 2DL3 tetramers to a panel of 97 HLA class I molecules. a Shown as
a heatmap by mean fluorescence intensity and percentage of maximum HLA-I ligand binding. b KIR2DL2 and c 2DL3 binding to individual HLA-I beads
represented in bar format with errors displayed as standard deviation. HLA are categorised by KIR-binding epitope, HLA-C1 (cyan), HLA-C2 (dark blue),
HLA A3/A11 (red). All data are representative of three independent experiments. The top 21 HLA ligands above background are shown. Error bars are
shown as mean with SD.
Table 1 KIR2DL2 and KIR2DL3 binding to HLA-C*07:02-










p value q value
WT 4.9 0.3 4.2 0.3 0.31 0.39
P7E n.d. n.d. n.d. n.d. n.d. n.d.
P7F 14.4 0.5 12.4 1.6 0.23 0.37
P7G 27.9 2.1 21.0 1.6 0.07 0.27
P7A 27.7 3.3 20.6 0.7 0.10 0.27
P7N 29.7 5.7 21.5 1.5 0.19 0.35
P7R 17.6 0.9 14.4 3.0 0.28 0.39
P8E n.d. n.d. n.d. n.d. n.d. n.d.
P8F 6.5 0.4 5.1 0.4 0.07 0.27
P8G 18.9 0.7 11.7 0.8 0.01 0.12
P8V 7.5 1.0 5.6 0.6 0.15 0.33
P8N 20.0 5.8 19.9 2.0 0.99 0.99
P8R 23.9 1.5 22.8 1.5 0.54 0.60
WT wild-type RL9 peptide (RYRPGTVAL), n.d. not determined, KD equilibrium dissociation
constant, SD standard deviation of calculated KD value.
KD values calculated via steady-state analysis of n= 2 injections of serially diluted KIR2DL
analyte described in full in Supplementary Fig. 6. Representative values of n= 2 independent
experiments are shown. Differences between KIR2DL2 and KIR2DL3 binding to each ligand was
assessed by multiple unpaired two-sample t-test using a false discovery rate (FDR) approach
(two-stage step-up method). p and q values for each comparison are shown. With a desired FDR
(Q) of 1%, no discoveries were observed.
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differences in their recognition did not strictly correlate with the
level of HLA-C expression (Fig. 5g). This suggested that other
allotypic features of these C1 molecules must also contribute to the
extent of their recognition by NK cells. Similarly, the differences in
inhibitory potency of different C1 allotypes did not strictly correlate
with the binding data from the Luminex analyses. This in part may
again reflect differences in the level of C1 allotype expression on the
transfected 221 cells but also reflect complex patterns of co-
expression of receptors, such as KIR2DS2 which is typically present
in conjunction with KIR2DL2 on B haplotypes which also have the
potential to recognise C1 allotypes.
Consequently, to directly compare the response of KIR2DL2+
cells in the absence of KIR2DS2 with those that expressed
KIR2DL3, we made use of the 1F12 mAb previously shown to
recognise KIR2DL3 and KIR2DS233. NK cells from donors who
were homozygous for KIR2DL3 or KIR2DL2/S2 were initially
Fig. 5 The functional response of KIR2DL2 and KIR2DL3 NK cells in the presence of HLA ligands. Enriched NK cells from healthy donors were cultured
with target cells and the degranulation response of NK cells expressing KIR2D assessed by flow cytometry. a The expression of HLA-C on both 721.221 and
Raji, Ramos and Namalwa lymphoma cell lines following staining with DT9 antibody (shaded grey area) is shown, with secondary antibody alone shown as
unfilled histogram. b Gating strategy for KIR2DL1/S1, KIR2DL2/S2 and KIR2DL3 NK cells. c Representative flow cytometry analysis of CD107a expression
on NK cell subsets from one donor in the presence of 721.221, Raji, Ramos and Namalwa cells is shown (gated on KIR3DL1− NK cells). d Pooled data
showing CD107a+ cells from six donors with six KIR2DL1/S1, and KIR2DL3 populations and four KIR2DL2/S2 populations is shown. Each symbol
represents an individual population of cells and bars depict mean ± SEM values. CD107a response is normalised to 721.221 response from the same
experiment. e Representative CD107a expression on NK cell subsets from one donor in the presence of either 721.221 cells or 721.221 cells transfected
HLA-C*06:02 or -C*07:02. f The degranulation response of KIR2D+ NK cells (GL183+ gated on a set GL183 MFI) to untransfected and HLA-C transfected
721.221 cells. Data are pooled from five donors. Each symbol represents data from an individual donor and bars depict mean ± SEM values. CD107a
response is normalised to 721.221 response. g The expression of different HLA-C on target cells stained with W6/32 antibody (shaded grey area) is shown
with 721.221 stain shown as black line. Statistical significance between KIR3DL2+ and KIR2DL3+ subsets (excluding KIR2DL1+) was tested using
Mann–Whitney test for all conditions; no symbol= p > 0.05; *p < 0.05; **p < 0.01. Each experiment has been performed twice with data from both
experiments pooled for the figure.
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stained with GL183 (KIR2DL2/L3/S2), REA147(KIR2DL3) and
1F12 (KIR2DL3/S2) demonstrating that KIR2DL3+ and
KIR2LD2+KIR2DS2- populations could be discriminated (Sup-
plementary Fig. 8). These subsets were also readily observed in
individuals who possessed both KIR2DL2 and KIR2DL3 (Fig. 6a,
Supplementary Fig. 8). The response of KIR2DL2+S2-L3- and
KIR2DL3+ subsets along with cells that expressed KIR2DS2 was
then compared in heterozygous donors. While each of these
populations had similar responses when stimulated with wild-
type 221 cells, those that expressed KIR2DS2 exhibited elevated
levels of activation relative to those that lacked KIR2DS2 upon
coculture with .221-HLA-C transfectants (Fig. 6b, Supplementary
Fig. 8). Indeed activation of the KIR2DS2+ population following
stimulation with 221-HLA-C*03:04 and -C*16:01 was similar to
that induced by untransfected 221 cells whereas cells expressing
HLA-C*07:02 or -C*12:03 stimulated similar but slightly weaker
responses. In contrast, the exclusion of KIR2DS2+ cells from the
KIR2DL2 gate, revealed that KIR2DL2+/2DS2− subset had a
similar pattern of C1 allotype recognition to the KIR2DL3+
subset against each HLA-C allotype tested. In some donors there
appeared to be preferential inhibition of KIR2DL3+ subset in
response to HLA-C*07:02 and HLA-C*16:01, but this was not
seen for all individuals perhaps reflecting allelic variation within
the KIR2DL2/3 genes. Furthermore, these similar patterns of C1-
induced inhibition between KIR2DL2+/S2− and KIR3DL3+ NK
cells were also evident in donors who were homozygous for either
KIR2DL2/S2 or KIR2DL3 (and lacking KIR2DS2), (Supplemen-
tary Fig. 8).
Again, the extent of inhibition varied with HLA-C allotype
consistent with the potential of these receptors to subtly modulate
the way they dock on different HLA-C/peptide complexes.
Together, the data suggest that despite differences in docking
mode, the functional response of NK cells expressing either
KIR2DL2 or KIR2DL3 to cells bearing a range of different HLA-C
allotypes was similar. This contrasted somewhat with the data
from the analyses of KIR2DL2/3 binding to bead-bound HLA-C
suggesting possible threshold effects above which subtle differ-
ences in the strength of interaction play at best a modest role in
determining the extent of inhibition.
Discussion
The interaction of KIR with their cognate HLA-I ligands plays a
dual role in NK cell function, acting to educate NK cells and
facilitate discrimination between healthy and abnormal cells. In
contrast to TCR recognition of HLA-I proteins that is typically
highly specific for particular HLA-I allotypes34, individual KIR
recognise multiple HLA-I allotypes that share conserved motifs.
While the structures of a number of KIR complexed to individual
HLA-I ligands have been determined28, it remained unclear
whether any given KIR interact with multiple HLA-I ligands in
precisely the same way, or whether different KIR that share HLA-
I ligands, recognise them in the same way. To address this, the
structures of KIR2DL2 complexed with HLA-C*07:02, and
KIR2DL3 complexed to HLA-C*07:02 were determined. Notably,
while KIR2DL2 and -2DL3 used essentially identical residues to
contact both HLA-I ligands, there were nevertheless differences in
the way each KIR2DL recognised HLA-C*03:04 and HLA-
C*07:02. This finding was supported by our mutational analysis
that showed KIR2DL2 and -2DL3 utilised a conserved con-
stellation of residues to bind different regions on pHLA-C com-
plexes. This unexpected capacity to use identical residues to make
alternate pHLA contacts appears to be driven by differences in
the juxtapositioning and specifically the twist of the D1 and D2
domains, and not by the D1-D2 interdomain angle as previously
suggested9,12. This sort of plasticity is somewhat similar to that
exhibited by the activating NK cell receptor NKG2D which
recognises a range of MHC class-like ligands, binding to them
with broadly similar docking modes, yet using similar residues in
the receptor to make quite distinct molecular contacts with dif-
ferent ligands35. Critically, this plasticity has the potential to
create a myriad of subtly distinct interaction modes of KIR2DL2
and KIR2DL3 with HLA-C peptide ligands. This likely impacts
the capacity of each to accommodate variations in the HLA-
bound peptide and ultimately drives differences in the recognition
of the complex array of ligands expressed on the cell surface by
each receptor.
SPR analyses of the KIR2DL interaction with HLA-
C*07:02 suggested that the affinity for each HLA-C/peptide
complex was broadly similar between KIR2DL2 and KIR2DL3.
Further, while substitutions at positions 7 and 8 clearly impacted
the affinity of these interactions, for the HLA-C*07:02-RL9
complex, they had similar impact on the binding of both
KIR2DL2 and 2DL3. Whether or not this is a general phenom-
enon or a particular feature of the HLA-C*07:02-RL9 remains to
be determined. Nevertheless, the data indicate that the affinity of































































Fig. 6 The functional response of KIR2DL2+S2− and KIR2DL3 NK cells. a Flow cytometry profile from one donor demonstrating gating strategy using
1F12 antibody. b Normalised responses of the gated populations following coculture either wild-type 221 cells or 221 cells transfected with HLA-C*03:04,
-C*07:02, -C*12:03 or -C*16:01 is shown. Data are pooled from eight to ten donors from two experiments. Each symbol represents an individual donor and
bars depict mean ± SEM values.
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In bead-binding assays and tetramer staining, we observed no
general pattern of binding superiority by KIR2DL2. This con-
trasted with previous studies using KIR2DL-Ig fusion proteins
which suggested that KIR2DL2 was a stronger and more peptide
tolerant receptor than KIR2DL312,36–38. There are significant
intrinsic differences between the refolded KIR2DL2/3 compared
with dimeric-KIR-Ig fusion proteins that include differences in
glycosylation and the oligomerisation of the receptor which may
impact docking geometries and/or modify the relative positioning
of the D1 and D2 domains when bound to HLA-C. The use of
tetrameric forms of KIR to probe the broader HLA specificity of
these receptors similarly found no systematic preferential binding
of KIR2DL2 to C1 allotypes over KIR2DL3. Rather, KIR2DL2
bound select allotypes, such as HLA-C*15:02 and -C*17:01 better
than KIR2DL3 which in turn had stronger interactions with
HLA-C*08:01 and -C*12:03 than KIR2DL2. Critically, given the
potential of peptide variation to impact KIR binding, these
broader specificity analyses of KIR2DL2 and -2DL3 used bead-
bound HLA-C complexed with a cellular-derived peptide reper-
toire rather than a single peptide. Thus while KIR2DL2 may bind
some HLA-C/peptide combinations better than KIR2DL3, our
data suggest that are also HLA-C/peptide combinations that will
be preferentially recognised by KIR2DL3. Moreover, given the
potential of peptide to modulate recognition, whether or not a
particular HLA-C allotype is preferentially bound by KIR2DL2 or
KIR2DL3 is likely dependent on the cellular peptide repertoire
and by implication the type of cell and potentially the extent to
which its repertoire is modified by transformation and/or
infection.
To better understand the extent to which these differences in
HLA-C binding impacted target cell recognition by NK cells
expressing KIR2DL2 or KIR2DL3, recognition of both tumour
cells and transfected cell lines expressing different HLA-C allo-
types was assessed. Our initial analyses again highlighted that
HLA-C allotypes differed in their capacity to inhibit primary NK
cells. Interestingly, the extent of inhibition observed did not cor-
relate with cell surface levels of HLA-C suggesting that allotypic
differences in HLA-C or in their associated peptide repertoires
impacted recognition in much the same way as had been observed
in binding analyses. However, the hierarchy of HLA-C allotype
recognition observed in our functional analyses did not strictly
correlate with that from the direct binding analyses. While the
binding of the recombinant KIR2DL2/3 to HLA-coated beads
exhibited the expected specificity for C1 allotypes, the extent to
which modest differences between allotypes would be manifest in
more physiological recognition settings is still unclear. For
example, consistent with previous work, both binding and in vitro
assays of cellular recognition indicate the HLA-C*07:02 is a strong
ligand for both KIR2DL2 and KIR2DL3, yet exactly where it sits in
the hierarchy of C1 allotypes is likely is impacted by numerous
factors. For example, both the nature of the peptide repertoire and
density of each HLA-C allotype present on the beads may sig-
nificantly impact the extent of KIR tetramer binding. Indeed, the
processes of purifying each HLA allotype and then generating
stably coated beads might ultimately bias the bead-associated
HLA-C to display a repertoire of peptides that has exceptional
capacity to stabilise the HLA relative to that present on the cell
surface. Similarly, the cellular analyses are also likely acutely
dependent on both the peptide repertoire present on the surface of
the target cell as well as the overall level of HLA-C expression.
Indeed, overexpression of the HLA-C allotypes as is likely in the
transfected 721.221 cells may well act to compress differences in
recognition by KIR2DL2/3. Similarly, in the functional analyses
NK cell intrinsic factors, such as differences in the KIR2DL2/3
allotpyes expressed, the co-expression of activating KIR2DS, and
education likely also contribute to functional outcomes, albeit that
similar responses were observed to 221 cells in all the donors who
possessed C1 alleles not only in KIR2DL2+/S2− and KIR2DL3+
cells but by those who expressed KIR2DS2.
The data here also provided some comparison of the relative
abilities of cells expressing either KIR2DL2 or KIR2DL3 to
recognise a range of HLA-C allotypes. Our initial analyses com-
paring the extent of C1 inhibition between cells expressing
KIR2DL3 with those that expressed either KIR2DL2 and/or
KIR2DS2 suggested it was greater in the KIR2DL3+ population.
However, upon exclusion of KIR2DS2+ cells, the responses of
KIR2DL2+2DS2- cells to 721.221 cells expressing HLA-C*03:04,
-C*07:02, -C*12:03 and -C*16:01 were each very similar to those
that expressed KIR2DL3. In contrast, cells expressing KIR2DS2
while having similar responses to both KIR2DL2+/S2− and
KIR2DL3+ cells to untranfected 721.221 cells, exhibited sig-
nificant degranulation responses to cells transfected with C1
allotypes, albeit that they were not greater than that elicited by the
parental 721.221 cells.
Taken together, our data highlight the potential for poly-
morphism in both receptor and ligand to regulate their mode of
interaction. Indeed, the data imply that allotypic differences in the
receptors, their HLA-I ligands and their associated peptide cargo
may each impact the interaction and ultimately the quality of
inhibitory signalling. Moreover, the impact of this genetically-
driven variation in the quality of KIR2D/HLA-I interaction is
essentially impossible to predict through sequence analysis alone.
Thus, studies that further refine the impact of polymorphism in
both receptors and ligands and that also account for the fre-
quency of cells expressing both these and genetically linked
receptors, such as KIR2DS2 will be needed to better understand
how this intricate network of innate receptor/ligand combinations
contributes to the control of infectious disease and cancer.
Methods
Cloning and expression of KIR2DL2 and KIR2DL3. The extracellular D1-D2
domains (residues 1–204) of KIR2DL2*001 and KIR2DL3*001 were cloned into
the expression vector pET-30(b) for expression in E. coli BL21 (DE3). The
receptors were expressed as inclusion bodies and refolded and purified24,39. Briefly,
100 mg of the KIR2DL1, -L2 and -L3 were refolded by rapid dilution in a buffer
containing 100 mM Tris-HCl pH 8.0, 400 mM L-arginine-HCl, 5 mM reduced
glutathione, and 0.5 mM oxidised glutathione for 72 h. The refolded receptors were
then applied onto a diethylaminoethyl (DEAE) cellulose column followed by size
exclusion chromatography using Superdex 200 16/60 column (GE Healthcare). The
KIR were further purified by anion exchange chromatography using Hi-Trap Q HP
5ml column (GE Healthcare).
Cloning and expression of HLA-C*03:04 and -C*07:02. The extracellular α1, α2
and α3 domains of HLA-C*03:04 and -C*07:02 (residues 1–276) and human β2-
macroglobulin (β2M) (residues 1–99) were cloned into the vector pET-30(b) for
expression in E. coli BL21 (DE3). HLA-C*03:04 and C*07:02 and β2M were
expressed separately into inclusion bodies and refolded in the presence of the
GAVDPLLAL and RYRPGTVAL peptides, respectively24,40. Overall, 90 mg of the
HLA heavy chain was refolded by rapid dilution in a buffer containing 100 mM
Tris-HCl pH 8.0, 400 mM L-arginine-HCl, 5 mM reduced glutathione and 0.5 mM
oxidised glutathione for 24 h, in the presence of 30 mg of β2 m and 10 mg of
peptide. The refolded receptors were then applied onto a DEAE cellulose column
followed by size exclusion chromatography using Superdex 200 16/60 column (GE
Healthcare). The HLA were further purified by anion exchange chromatography
using Hi-Trap Q HP 5ml column (GE Healthcare). BirA-tagged HLA-C were
generated by this refolding method and enzymatically biotinylated with biotin
ligase for the generation of HLA-C tetramers41.
Surface plasmon resonance. SPR experiments were performed on a BIAcore
T3000 machine. Three independent experiments using different batches of protein
were performed at 298 K in a buffer containing 10 mM HEPES pH 7.4, 150 mM
NaCl and 0.05% Tween 20. The HLA-Class I specific monoclonal antibody W6/32
was coupled to four flow cells of a CM5 sensorchip (BIAcore) by amine coupling
(~1000 resonance units (RU)). HLA-C*07:02 and alanine scanning mutants were
captured by W6/32 to a density of ~150–200 RU. KIR2DL2 and 2DL3 were serially
diluted in 10 mM HEPES pH 7.4, 150 mM NaCl, 0.05% Tween 20 (0–50 μM) and
passed simultaneously over the test (HLA-C) and control (w6/32 alone) flow cells
surfaces at a flow rate of 30 μl/min, with measurements taken in duplicate. The
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obtained data were analysed using Prism (GraphPad) by steady-state equilibrium
analysis following subtraction of control surface.
Crystallisation, data collection, structure determination and refinement.
KIR2DL2 and KIR2DL3 were each concentrated to 10 mg/ml and added separately
to HLA-C*07:02-RL9 at a 1:1 molar ratio. Crystals were obtained at 20 °C using the
hanging drop vapour-diffusion method. Crystals of the KIR2DL2-HLA-C*07:02-
RL9 complex were obtained from a solution consisting 0.2 M Sodium tartrate
dibasic dihydrate and 20% w/v PEG 3350. Crystals of the KIR2DL3-HLA-C*07:02-
RL9 complex were obtained from a solution containing 0.2 M Ammonium acetate,
0.1 M Tris-HCl pH.8.0 and 25% PEG 3350. Prior to flash-cooling in liquid nitrogen
at 100 K, all crystals were equilibrated in a cryoprotectant solution containing their
respective crystallisation solution and 35% PEG 3350. Data sets for the KIR2DL2
and KIR2DL3-HLA-C*07:02-RL9 complexes were collected to 3.1 Å and 2.5 Å
respectively at the MX1 beamline (Australian Synchrotron, Victoria). The data
were recorded on a Quantum-315 CCD detector and integrated and scaled using
the HKL/HKL-2000 programme package42 (data collection statistics are sum-
marised in Supplementary Table 1). Structural determination proceeded by
molecular replacement using PHASER, within the CCP4 programme suite43 with
the previously determined KIR2DL2-HLA-C*03:04 structure utilised as the search
model (PDB accession code: 1EFX24). Both the KIR2DL2 and 2DL3 crystals
comprised two copies of their respective complexes in the asymmetric unit.
Refinement of the complexes progressed with iterative rounds of manual building
in COOT44 and refinement in PHENIX45 with twofold non-crystallographic
symmetry restraints applied throughout. The final model of the KIR2DL2-HLA-
C*07:02-RL9 complex comprises residues 4–190. The final model of the KIR2DL3-
HLA-C*07:02-RL9 complex comprises residues 6–195. The structures were vali-
dated with MOLPROBITY46. The KIR2DL2 and 2DL3-HLA-C*07:02-RL9 com-
plexes were deposited in the Protein Databank under accession codes 6PA1 and
6PAG, respectively (https://doi.org/10.2210/pdb6PA1/pdb and https://doi.org/
10.2210/pdb6PAG/pdb).
KIR2DL2 and 2DL3 mutagenesis and transfection. Full-length constructs of
KIR2DL2 and KIR2DL3 were cloned into the pEF6 vector with a FLAG tag at the
N-terminus of the coding sequence. Site-directed mutagenesis (QuikChange II,
Stratagene) was used to generate mutants of KIR2DL2 and KIR2DL3, in order to
study the contribution of particular amino acids located on their ectodomains to
HLA-I recognition (Supplementary Table 3). Transfection of all constructs into
HEK293T cells was accomplished using FuGENE 6 transfection reagent (Roche)
based on the manufacturer’s instructions. HEK293T cell transfectants expressing
wild-type or mutant KIR2DL2 and KIR2DL3 were stained with HLA-C tetramers
and/or anti-FLAG (clone M2; Sigma-Aldrich) mAb for 30 min at 277 K and then
analysed by flow cytometry.
Single-antigen bead assay. HLA-I recognition by KIR2DL2 and 2DL3 and
mutants thereof was assessed through the use of a multiplexed bead assay. Briefly,
5 µg of PE-conjugated KIR tetramers were incubated for 30 min at room tem-
perature with beads coated with a panel of 100 different HLA-A, B and C molecules
(LABScreen HLA Class I Single Antigen; One Lambda). Samples were processed
according to the manufacturer’s instructions using LABScreen Wash Buffer (One
Lambda) and binding measured on a Luminex platform (LABScan 100; One
Lambda). Interactions with individual HLA allotypes were distinguished via unique
bead labelling and detection of tetramer fluorescence intensity. Normalised fluor-
escence values were obtained using the HLA Fusion software suite (One Lambda)
using Eq. 1:
ðS#N  SNC beadÞ  ðBG#N  BGNC beadÞ; ð1Þ
where S#N is the sample-specific fluorescence value (trimmed mean) for bead #N,
SNC bead is the sample-specific fluorescence value for the negative control (nude)
bead, BG#N is the background negative control fluorescence value for bead #N, and
BGNC bead is the background negative control fluorescence value for negative
control bead. Negative control samples were obtained using an isotype control (PE-
conjugated anti-human IgG –One Lambda) and were subtracted from the raw
values obtained for each experiment. Recognition was assessed as being higher than
that of the tetramer to beads without conjugated HLA-I. MFI values were nor-
malised to the highest value for each experiment and then averaged over three
experiments.
Degranulation assays. Cryopreserved PBMCs from healthy blood bank donors
were thawed and washed several times before NK cells were enriched using
EasySep human NK enrichment kit (Stemcell Technologies) as per the manu-
facturer’s instructions. NK cells were cultured overnight in 100 U/ml recombinant
human IL-2 (IS premium grade, Miltenyi Biotec). NK cells were incubated with
target cells at a 1:1 ratio for 5 h. In all experiments, CD94-NKG2A was blocked
with supernatant from the Y9 hybridoma (kind gift from Gabriella Pietra, Uni-
versity of Genova, Italy) added 30 min before the assay, and maintained in the
culture throughout the assay. Antibody to CD107a PE, PECy5 or PECy7 (clone
H4A3; BD Biosciences; at 1:100 final dilution) was added at the beginning of the
culture followed by Golgi Stop (Monensin, BD Biosciences). The following cell
lines were used as targets for functional assays: HLA-deficient B lymphoblastoid
cell line 721.221 (.221); .221 cells stably transfected with HLA-C1 and C2; Burkitt’s
lymphoma cell lines used were Raji (HLA-A*03:01, B*15:10, C*03:04/C*04:01),
Ramos (HLA-A*03:01, B*44:160Q/51:01, C*16:01) and Namalwa (HLA-A*03:01/
68:02, B*07:02, B*49:01, C*07:01/07:02) sequenced by Victorian Transplantation
and Immunogenetics Service, Melbourne, Australia. The experiments were per-
formed in accordance with approvals from the Human Research Ethics Committee,
University of Melbourne.
Flow cytometry. Single-cell suspension was incubated in staining antibody cocktail
containing a combination of following antibodies: CD56 BV421 (clone NCAM16.2;
BD Biosciences; 1:50 dilution), CD56 APC or PE (clone B159; BD Biosciences; 1:50
dilution), KIR3DL1 APC (clone DX9; BD Biosciences 1:50 dilution), CD3 APCCy7
(clone SK7; BD Biosciences; 1:100 dilution), KIR2DL2/L3/S2 PECy5.5 (clone
GL183; Beckman Coulter; 1:50-1:200 dilution), KIR2DL2/L3/S2 BUV737 (clone
CH-L; BD Biosciences; 1:50 dilution), KIR2DL1/S1 PECy7 or APC (clone EB6;
Beckman Coulter; 1:50 dilution), KIR2DL3 FITC (clone REA147; Miltenyi Biotech;
1:50 dilution), fixable viability dye eFluor780 (Life Research; 1:500 dilution). Cells
were surface stained in FACS buffer (PBS containing 2% FCS and 5 mM EDTA) on
ice, in dark for 30 min after which they were washed twice and fixed using BD
Cytofix/Cytoperm kit (BD Pharmingen). Staining with the KIR2DL3/S2 spe-
cific antibody 1F12 (EFS, Nantes, France) employed a multi-step protocol with a
secondary antibody and was performed as follows: cells were initially incubated
with a goat anti-mouse IgG antibody (polyclonal; Invitrogen) for 30 min on ice to
block secondary Ab-binding sites on cell-bound CD107a-specific mAb before
incubation with purified mouse anti-human 1F12 antibody (1:50 dilution), fol-
lowed by secondary goat anti-mouse IgG BV421 antibody (clone poly4053; Bio-
legend; 1:50 dilution). After washing, cells were incubated in FACS buffer with
normal mouse serum (Thermo Fisher Scientific) before adding the remaining
antibody cocktail and fixing the cells.
All flow cytometry experiments were performed on Flow Cytometers BD LSRII
or BD LSR Fortessa. Analysis was performed using FlowJo software (Tree Star).
Gating strategy included the elimination of dead cells positive for fixable viability
stain, CD3 antibody stain and doublets, including the exclusion of cells based on
size and granularity using FSC/SSC discrimination. NK cells were identified as
viable, CD3-lymphocytes, positive for CD56. Target cells were analysed for the
expression of HLA I (clone w6/32) and HLA-C (clone DT9; Sigma; dilution 1:50).
Secondary antibody chicken anti-mouse IgG AF488 (Life Technologies; dilution
1:100) was used to identify a positive stain. Gating strategies for NK cell subset
analyses are provided (Supplementary Fig. 9).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
All data are available upon request from the authors. Crystal structures of the KIR2DL2
and KIR2DL3-HLA-C*07:02-RL9 complexes were deposited in the Protein Databank
under accession codes 6PA1 and 6PAG, respectively. Source data are provided with
this paper.
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